Research programme: siDNA anticancer therapeutics - OnxeoAlternative Names: DT02; siDNA - Onxeo; Small inhibitory DNA - Onxeo; Xbait
Latest Information Update: 06 May 2016
At a glance
- Originator DNA Therapeutics
- Developer Onxeo SA
- Mechanism of Action DNA repair inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Dec 2011 Preclinical development is ongoing in France